Targeting WTAP sensitizes hepatocellular carcinoma to sorafenib by inhibiting the ERK signaling pathway - PubMed
3 hours ago
- #ERK pathway
- #Sorafenib resistance
- #Hepatocellular carcinoma
- Targeting WTAP sensitizes hepatocellular carcinoma (HCC) to sorafenib by inhibiting the ERK signaling pathway.
- WTAP is upregulated in HCC tissues and associated with tumor progression and poor clinical outcomes.
- Knockdown of WTAP enhances HCC cell sensitivity to sorafenib in vitro.
- WTAP activates the ERK signaling pathway, contributing to sorafenib resistance.
- Combining WTAP knockdown with sorafenib treatment suppresses tumor progression and improves survival in mouse models.
- The study suggests targeting WTAP as a novel strategy to improve sorafenib efficacy in HCC.